Nov. 11 at 1:32 AM
$AQST
Neffy market share was just reported at about 3.74%. They are underperforming vs their launch projections , and
$SPRY investors have good reason to be concerned about the Anaphylm launch.
Anaphylm’s competition isn’t Neffy - Aquestive isn’t putting a lowly 3.75% target in their crosshairs. EpiPen has almost 70% market share, and they are the primary targeted competition. Other injector mfgs are greater competitive targets than Neffy. Nothing to this point has degraded AQSTs upcoming threat to the market leaders. Neffy has been a commercial disappointment for reasons unique to the product and the ARS launch execution. AQST has stronger professionals leading their launch and they have the benefit of learning from SPRY’s mistakes and not repeating them in the Anaphylm launch.
Hey, I get it, SPRY investors are scared, and they seem to think that attacking AQST on messaging boards will help their cause. They’ve lost money on that investment. Cut your losses!
